Friday, May 1, 2026

Coupang’s Harold Rogers Faces U.S. Congress: What Will He Reveal About the Data Breach?

Coupang's interim CEO testifies before the U.S. House Judiciary Committee amid investigations of data breaches and regulatory scrutiny.

KIM’S DIGITAL SHACKLES: New GPS Smartwatch Turns 25 Million Citizens Into Human Tracking Chips

North Korea's first smartwatch, the Sujeong Cheon 5010, features GPS and health monitoring, raising concerns over citizen surveillance.

North Korea’s Shift in Strategy: Nuclear Weapons, Hostility Toward the U.S. and South Korea

North Korea's policy designating the U.S. and South Korea as 'enemies' is linked to its five-year defense development plan.

Tag: Novo Nordisk

North KoreaKoreaKimMilitarySouth KoreaAImarketrelationsInternational

Top 3 Innovative Korean Biotech Firms Shine at Novo Nordisk Partnering Day 2026

Novo Nordisk Korea hosted Partnering Day 2026 to foster global partnerships in healthcare, highlighting innovative local biotech firms.

Will Novo Nordisk’s 50% Price Cut on Wegovy Spark a Price War in Korea’s Obesity Drug Market?

Novo Nordisk's price cuts for GLP-1 obesity treatments in the U.S. may influence South Korean market dynamics, though immediate effects seem limited.

Novo Nordisk Slashes GLP-1 Drug Prices by Up to 50%: What This Means for Obesity Treatments in 2027

Novo Nordisk will cut prices of GLP-1 treatments in the U.S. by up to 50% from January 2027, amid rising competition and market pressures.

Eli Lilly vs. Novo Nordisk: A $1.2 Billion Bet Reveals Two Very Different Futures for Obesity Drugs

Eli Lilly and Novo Nordisk are pursuing different strategies in the obesity treatment market, focusing on expansion versus core strengths.

Novo Nordisk’s Wegovy Pill Draws 3,000 Prescriptions in Its First Week—Is Oral GLP-1 Here to Stay?

Novo Nordisk's Wegovy oral obesity treatment saw over 3,000 prescriptions in its first week, indicating strong market demand.

Patches, Implants, and Oral Films… The Drug-Delivery Format Battle After Oral Wegovy

Oral Wegovy's launch is transforming obesity treatment, focusing on user-friendly delivery methods and enhancing patient adherence.

Wegovy Gets Stronger: New Dose Promises Even More Weight Loss

Novo Nordisk's new high-dose Wegovy aims to enhance obesity treatment, with promising trial results and a strategic EU rollout planned.

Rising Use of GLP-1 Drugs May Be Linked to Rare Pancreatitis Cases, Study Finds

Reports of acute pancreatitis linked to GLP-1 diabetes drugs surge in the UK, prompting investigations and conflicting academic findings.

Ozempic Maker Swaps CEO, Bets $2.2B on New Obesity Drug Fight

Novo Nordisk's leadership change aims to reclaim its obesity treatment market share amid competition from Eli Lilly's Mounjaro.

New Study: Mounjaro Helps Users Drop Over 50 Pounds

Eli Lilly's Mounjaro leads U.S. obesity drug market, outperforming semaglutide in weight loss efficacy and safety.

Novo Nordisk Pushes for First Oral Obesity Drug Approval

Novo Nordisk seeks FDA approval for oral Wegovy, potentially the first oral obesity treatment, amid competition with Eli Lilly.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.